353 related articles for article (PubMed ID: 34076441)
1. Recent Advances in the Development of Sigma Receptor Ligands as Cytotoxic Agents: A Medicinal Chemistry Perspective.
Fallica AN; Pittalà V; Modica MN; Salerno L; Romeo G; Marrazzo A; Helal MA; Intagliata S
J Med Chem; 2021 Jun; 64(12):7926-7962. PubMed ID: 34076441
[TBL] [Abstract][Full Text] [Related]
2. Structure-activity relationships of mixed σ
Fallica AN; Ciaffaglione V; Modica MN; Pittalà V; Salerno L; Amata E; Marrazzo A; Romeo G; Intagliata S
Bioorg Med Chem; 2022 Nov; 73():117032. PubMed ID: 36202063
[TBL] [Abstract][Full Text] [Related]
3. Computer-assisted design, synthesis, binding and cytotoxicity assessments of new 1-(4-(aryl(methyl)amino)butyl)-heterocyclic sigma 1 ligands.
Zampieri D; Vio L; Fermeglia M; Pricl S; Wünsch B; Schepmann D; Romano M; Mamolo MG; Laurini E
Eur J Med Chem; 2016 Oct; 121():712-726. PubMed ID: 27366902
[TBL] [Abstract][Full Text] [Related]
4. Sigma Receptor (σR) Ligands with Antiproliferative and Anticancer Activity.
Georgiadis MO; Karoutzou O; Foscolos AS; Papanastasiou I
Molecules; 2017 Aug; 22(9):. PubMed ID: 28841173
[TBL] [Abstract][Full Text] [Related]
5. Exploring the Selectivity Profile of Sigma Receptor Ligands by Molecular Docking and Pharmacophore Analyses.
Righetti G; Tonelli M; Fossa P; Cichero E
Med Chem; 2021; 17(10):1151-1165. PubMed ID: 33155928
[TBL] [Abstract][Full Text] [Related]
6. Structure-Activity Relationships within a Series of σ
Franchini S; Sorbi C; Battisti UM; Tait A; Bencheva LI; Cichero E; Fossa P; Cilia A; Prezzavento O; Ronsisvalle S; Aricò G; Benassi L; Vaschieri C; Azzoni P; Magnoni C; Brasili L
ChemMedChem; 2017 Nov; 12(22):1893-1905. PubMed ID: 28940806
[TBL] [Abstract][Full Text] [Related]
7. Antiproliferative and cytotoxic effects of some sigma2 agonists and sigma1 antagonists in tumour cell lines.
Colabufo NA; Berardi F; Contino M; Niso M; Abate C; Perrone R; Tortorella V
Naunyn Schmiedebergs Arch Pharmacol; 2004 Aug; 370(2):106-13. PubMed ID: 15322732
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and pharmacological evaluation of benzannulated derivatives as potent and selective sigma-1 protein ligands.
Donnier-Maréchal M; Carato P; Le Broc D; Furman C; Melnyk P
Eur J Med Chem; 2015 Mar; 92():575-82. PubMed ID: 25602932
[TBL] [Abstract][Full Text] [Related]
9. Discovery of new potent dual sigma receptor/GluN2b ligands with antioxidant property as neuroprotective agents.
Zampieri D; Fortuna S; Calabretti A; Romano M; Menegazzi R; Schepmann D; Wünsch B; Collina S; Zanon D; Mamolo MG
Eur J Med Chem; 2019 Oct; 180():268-282. PubMed ID: 31319263
[TBL] [Abstract][Full Text] [Related]
10. Combination of Heme Oxygenase-1 Inhibition and Sigma Receptor Modulation for Anticancer Activity.
Romeo G; Ciaffaglione V; Amata E; Dichiara M; Calabrese L; Vanella L; Sorrenti V; Grosso S; D'Amico AG; D'Agata V; Intagliata S; Salerno L
Molecules; 2021 Jun; 26(13):. PubMed ID: 34202711
[TBL] [Abstract][Full Text] [Related]
11. Synthesis, binding, and functional properties of tetrahydroisoquinolino-2-alkyl phenones as selective σ
Xie XY; Li YY; Ma WH; Chen AF; Sun YT; Lee JY; Riad A; Xu DH; Mach RH; Huang YS
Eur J Med Chem; 2021 Jan; 209():112906. PubMed ID: 33049607
[TBL] [Abstract][Full Text] [Related]
12. Medicinal Chemistry of σ
Weber F; Wünsch B
Handb Exp Pharmacol; 2017; 244():51-79. PubMed ID: 28620761
[TBL] [Abstract][Full Text] [Related]
13. Synthesis of bicyclic sigma receptor ligands with cytotoxic activity.
Geiger C; Zelenka C; Weigl M; Fröhlich R; Wibbeling B; Lehmkuhl K; Schepmann D; Grünert R; Bednarski PJ; Wünsch B
J Med Chem; 2007 Nov; 50(24):6144-53. PubMed ID: 17967001
[TBL] [Abstract][Full Text] [Related]
14. Classes of sigma2 (σ2) receptor ligands: structure affinity relationship (SAfiR) studies and antiproliferative activity.
Abate C; Perrone R; Berardi F
Curr Pharm Des; 2012; 18(7):938-49. PubMed ID: 22288411
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and Pharmacological Evaluation of σ2 Receptor Ligands Based on a 3-Alkoxyisoxazole Scaffold: Potential Antitumor Effects against Osteosarcoma.
Shi JJ; Jia KH; Sun H; Gunosewoyo H; Yang F; Tang J; Luo J; Yu LF
ChemMedChem; 2021 Feb; 16(3):524-536. PubMed ID: 32964625
[TBL] [Abstract][Full Text] [Related]
16. Synthesis, in vitro and in vivo characterization of new benzoxazole and benzothiazole-based sigma receptor ligands.
Romeo G; Prezzavento O; Intagliata S; Pittalà V; Modica MN; Marrazzo A; Turnaturi R; Parenti C; Chiechio S; Arena E; Campisi A; Sposito G; Salerno L
Eur J Med Chem; 2019 Jul; 174():226-235. PubMed ID: 31042618
[TBL] [Abstract][Full Text] [Related]
17. The Molecular Function of σ Receptors: Past, Present, and Future.
Schmidt HR; Kruse AC
Trends Pharmacol Sci; 2019 Sep; 40(9):636-654. PubMed ID: 31387763
[TBL] [Abstract][Full Text] [Related]
18. Design, Synthesis, and Cytotoxic Assessment of New Haloperidol Analogues as Potential Anticancer Compounds Targeting Sigma Receptors.
Zampieri D; Romano M; Fortuna S; Amata E; Dichiara M; Cosentino G; Marrazzo A; Mamolo MG
Molecules; 2024 Jun; 29(11):. PubMed ID: 38893570
[TBL] [Abstract][Full Text] [Related]
19. A Medicinal Chemist's Perspective Towards Structure Activity Relationship of Heterocycle Based Anticancer Agents.
Nehra B; Mathew B; Chawla PA
Curr Top Med Chem; 2022; 22(6):493-528. PubMed ID: 35021975
[TBL] [Abstract][Full Text] [Related]
20. Benzimidazolone-based selective σ
Intagliata S; Alsharif WF; Mesangeau C; Fazio N; Seminerio M; Xu YT; Matsumoto RR; McCurdy CR
Eur J Med Chem; 2019 Mar; 165():250-257. PubMed ID: 30685525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
